Eye redness is common and can develop after exposure to dust, dry air, environmental irritants, or other factors that affect the eye’s surface. Although redness-relieving eye drops have been available for years, a newly approved nonprescription treatment offers consumers another option.
On October 16, 2026, the U.S. Food and Drug Administration (FDA) approved Brytly (apraclonidine ophthalmic solution 0.125%), developed by Alcon, for temporary relief of eye redness caused by minor irritations. It is the first nonprescription eye drop containing apraclonidine, according to the FDA. The product is approved for adults and children aged 12 and older, with use limited to no more than twice daily. Read the FDA announcement.
The approval expands the range of products available for managing minor eye redness. However, understanding how these drops work, how they differ from other redness relievers, and when redness requires medical attention is essential for safe use.
What Is Brytly, and How Does It Work?
Brytly contains apraclonidine, an ingredient previously available in higher-strength prescription eye drops used to help lower intraocular pressure in certain eye conditions and following some laser procedures.
The newly approved 0.125% formulation has a different purpose: temporary relief of redness associated with minor eye irritation.
Eye redness generally occurs when blood vessels on the surface of the eye become enlarged or more visible. This can happen for several reasons, including environmental irritation and dryness. Redness-relieving drops work by constricting certain blood vessels, making the eyes appear less red.
The specific effects, precautions, and recommended frequency depend on the formulation. Consumers should follow Brytly’s approved Drug Facts label rather than assume that instructions for other eye drops apply to it.
How Does Brytly Compare With Older Redness-Relief Drops?
Traditional over-the-counter eye redness relievers may contain ingredients such as tetrahydrozoline or naphazoline. These medications constrict blood vessels to reduce visible redness.
Another option is brimonidine tartrate 0.025%, marketed in the United States as Lumify. Brytly introduces a different active ingredient into the nonprescription category.
Although these products share a similar cosmetic purpose, they are not interchangeable in every respect.
Key differences include:
- Active ingredient: Traditional products may contain tetrahydrozoline or naphazoline, while Lumify contains brimonidine and Brytly contains apraclonidine.
- Dosing instructions: The maximum permitted frequency varies by product. The FDA says Brytly should not be used more than twice daily.
- Duration of relief: The duration depends on the specific product and its approved labeling. Alcon reports that Brytly can reduce redness for up to 12 hours; this is a manufacturer-reported product claim, not a guarantee that every user will experience the same result.
- Potential for recurrent redness: Some redness-relieving drops can cause redness to return or worsen with repeated use. A product’s suitability and risk profile should be assessed according to its own labeling and clinical evidence.
The new approval is a development in nonprescription eye care, but it does not mean that every cause of eye redness can be safely treated with whitening drops.
What Should Consumers Know Before Using Brytly?
The FDA provides several important instructions for consumers considering Brytly.
1. Follow the Age and Dosing Restrictions
Brytly is approved for adults and children aged 12 years and older. It should not be used more than twice in a 24-hour period.
Using more drops than directed does not necessarily improve results and may increase the risk of unwanted effects. Read the complete product label before use.
2. Remove Contact Lenses Before Applying the Drops
Contact lens wearers should remove their lenses before using Brytly. According to the FDA, they should wait at least 10 minutes after applying the drops before reinserting their lenses.
Follow the product label and seek professional advice if you are unsure whether the drops are appropriate for your type of contact lenses.
3. Allow Time Between Different Eye Drops
If you use other ophthalmic products, the FDA advises waiting at least five minutes between applications to help prevent one product from washing out another.
If you use prescription eye medication, check with your eye-care professional or pharmacist before adding a new redness reliever.
4. Know When to Stop Using the Product
The FDA advises consumers to stop using Brytly and ask a doctor for advice if they experience eye pain, vision changes, continued redness or irritation, or if symptoms worsen or persist for more than three days.
These warnings are important because redness is a symptom, not a diagnosis. Temporary cosmetic improvement does not necessarily mean that the underlying cause has resolved.
When Is Eye Redness a Reason for Medical Attention?
Not all red eyes result from minor irritation. Some causes require prompt treatment, and redness-relieving drops should not be used to delay an eye examination.
Seek urgent medical assessment if redness is accompanied by any of the following:
- Eye pain or significant discomfort: Pain can indicate a problem beyond routine irritation.
- Blurred or reduced vision: Any new change in vision warrants prompt assessment.
- Sensitivity to light: Photophobia can occur with conditions affecting the cornea or other internal structures of the eye.
- A painful red eye in a contact lens wearer: Contact lens-related corneal infections can threaten vision and need urgent evaluation.
- Severe redness with headache, nausea, or halos around lights: These symptoms can occur with acute angle-closure glaucoma, an eye emergency.
If you suspect a serious eye problem, do not try to manage it solely with cosmetic redness-relief drops.
What If Redness Keeps Coming Back?
Repeated redness may be associated with dry eye disease, allergies, eyelid inflammation, infection, contact lens irritation, or other eye conditions.
For example, people with dry eyes may benefit from lubricating artificial tears and changes to their environment or screen habits. Allergy-related symptoms may require a different treatment approach. Persistent eyelid irritation or recurring redness may need evaluation by an optometrist or ophthalmologist.
Using redness-relief drops repeatedly without identifying the cause can delay appropriate treatment. If symptoms keep returning, professional assessment is a better long-term strategy than relying on whitening drops alone.
The Bottom Line
The FDA’s approval of Brytly introduces apraclonidine 0.125% as a new nonprescription option for temporary relief of minor eye redness in adults and children aged 12 and older. Its approval expands consumer choice, while the dosing restrictions and stop-use warnings underscore the importance of using eye medications carefully.
Brytly is intended for minor irritation, not for diagnosing or treating every condition that makes the eyes red. Consumers should read the Drug Facts label, follow the recommended limits, and seek medical advice when redness persists, worsens, or occurs with pain or changes in vision.
The most important rule is simple: reducing redness does not necessarily mean the underlying eye problem has been treated.
🩺 Editorial Note & Medical Disclaimer
The information provided on healandnourish.com is intended for educational and informational purposes only and should not be construed as professional medical or ophthalmic advice. Eye redness can be the first presentation of severe ocular conditions. If you experience acute eye pain, vision changes, intense photophobia, or discharge, seek immediate evaluation from a licensed optometrist, ophthalmologist, or emergency eye clinic.
References & Clinical Resources
- U.S. Food and Drug Administration (FDA): Access the official CDER drug approval announcement and label specifications for Brytly (apraclonidine ophthalmic solution 0.125%) via the FDA Drug Alerts and Statements Portal.
- American Academy of Ophthalmology (AAO): Review preferred practice patterns regarding the differentiation of conjunctival hyperemia, red eye triage, and the risks of topical vasoconstrictors at the AAO Eye Care Quality Network.
- Investigative Ophthalmology & Visual Science (IOVS): Explore peer-reviewed data on the comparative microvascular selectivity of alpha-2 adrenergic agonists in conjunctival venules at the ARVO IOVS Archive.
- Clinical Ophthalmology: Access literature reviewing the mechanism of conjunctivitis medicamentosa and rebound vasodilation caused by non-selective adrenergic amines via the Dove Medical Press Portal.
